GD-ANIDULAFUNGIN DIN 02441683
Health Canada record
| Active ingredient(s) | ANIDULAFUNGIN 100 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J02AX06 ANIDULAFUNGIN |
| Original market date | |
| Current status date | 15-Jan-2021 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ANIDULAFUNGIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02330695 | ERAXIS | PFIZER CANADA ULC | Powder For Solution | ANIDULAFUNGIN 100 MG | Marketed |
| 02302160 | ERAXIS | PFIZER CANADA ULC | Powder For Solution | ANIDULAFUNGIN 100 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18163 | 2016-06-08 | New Drug Submission (NDS) | LICENSING AGREEMENT BETWEEN TWO COMPANIES |
International API supply for ANIDULAFUNGIN
3 active FDA Drug Master Files.
Request a quote for GD-ANIDULAFUNGIN